跳至主要内容
临床试验/TCTR20260726005
TCTR20260726005进行中(未招募)早期 1 期

EUS-guided Portal Vein Sampling for Circulating Tumor Cells to Predict Treatment Response Compared with CT Imaging in Unresectable Pancreatic Ductal Adenocarcinoma: A Prospective Observational Study

Faculty of Medicine, Chulalongkorn University0 个研究点目标入组 32 人开始时间: 2026年8月1日最近更新:
适应症

试验速览

阶段
早期 1 期
状态
进行中(未招募)
入组人数
32

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 80 Years(—)
性别
All

入选标准

  • Histologically confirmed non metastatic pancreatic ductal adenocarcinoma classified as AJCC stage I to III
  • Disease assessed as unresectable by a multidisciplinary team
  • Planned to receive chemotherapy radiotherapy or combined treatment according to standard care
  • Eastern Cooperative Oncology Group performance status 0 to 2
  • Estimated life expectancy of at least 6 months
  • Able and willing to provide written informed consent

排除标准

  • Uncorrectable coagulopathy defined as INR greater than 1.5 activated partial thromboplastin time greater than two times the upper limit of normal or platelet count less than 50000 after appropriate correction
  • Uncontrolled infection or sepsis
  • Poor visualization of the portal vein during endoscopic ultrasound
  • Contraindication to upper gastrointestinal endoscopy or sedation
  • Unable or unwilling to comply with study procedures or follow up

研究者

相似试验